Association of genetically predicted lipid traits and lipid-modifying targets with heart failure
- PMID: 36520639
- DOI: 10.1093/eurjpc/zwac290
Association of genetically predicted lipid traits and lipid-modifying targets with heart failure
Abstract
Aims: To assess the association of genetically predicted lipid traits and lipid-modification via licensed or investigational targets with heart failure (HF).
Methods and results: Two-sample Mendelian randomization (MR) study was conducted using summary-level genome-wide association studies (GWASs) from UK Biobank and HERMES Consortium. Genetic variants obtained from UK Biobank GWAS data were selected as instrumental variables to predict the level of lipid traits [LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), triglyceride (TG), apolipoprotein B (ApoB), and apolipoprotein AI (ApoAI)] and lipid-modifying effect of eight drug targets [HMGCR, PCSK9, NPC1L1, PPARA, lipoprotein lipase (LPL), ANGPTL3, APOC3, and cholesteryl ester transfer protein (CETP)]. In this study, we observed that genetically predicted LDL-C, TG, HDL-C or ApoB were significantly related to HF, which were mainly mediated by coronary heart disease (CHD). Drug target MR analyses identified PCSK9, CETP, and LPL as potential targets to prevent HF. The genetic proxy of LDL-C and ApoB increase modified by PCSK9 showed similar evidence in increasing risk of HF (PLDL-C = 1.27*10-4; PApoB = 1.94*10-4); CETP played a role in HF risk via modifying all investigational lipid traits with the strongest evidence though ApoB (P = 5.87*10-6); LPL exerted effects on HF via modifying most lipid traits with the strongest evidence observed via modifying TG (P = 3.73*10-12).
Conclusion: This two-sample MR study provided genetic evidence of the associations between lipid traits and HF risk, which were mostly mediated by CHD. Besides, drug target MR studies indicated that PCSK9 inhibition, CETP inhibition, and LPL activation were effective in HF reduction.
Keywords: Heart failure; Lipids; Mendelian randomization.
Plain language summary
Dyslipidaemia is a well-established cause of CHD, but the relationship between lipids and heart failure (HF) is unclear, and it is still unknown if lipid-modifying treatment could prevent HF. This study provided genetic evidence that dyslipidaemia is related to a higher risk of HF, mainly through the increased risk of CHD. This study identified three drug targets that may reduce the risk of HF via modifying lipids, including PCSK9 inhibition, CETP inhibition, and LPL activation.
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Conflict of interest statement
Conflict of interest: The authors declared no potential conflicts of interest regarding the research, authorship, and publication of this article.
Comment in
-
Primary prevention of heart failure: targeting dyslipidemia and atherosclerotic pathways.Eur J Prev Cardiol. 2023 Feb 20:zwad044. doi: 10.1093/eurjpc/zwad044. Online ahead of print. Eur J Prev Cardiol. 2023. PMID: 36804691 No abstract available.
Similar articles
-
Mendelian randomization study of lipid metabolism characteristics and migraine risk.Eur J Pain. 2024 Jul;28(6):978-986. doi: 10.1002/ejp.2235. Epub 2024 Jan 6. Eur J Pain. 2024. PMID: 38183343
-
Lipids, lipid-modifying drug target genes and migraine: a Mendelian randomization study.J Headache Pain. 2023 Aug 18;24(1):112. doi: 10.1186/s10194-023-01633-x. J Headache Pain. 2023. PMID: 37596566 Free PMC article.
-
Associations of Lipids and Lipid-Lowering Drugs with Risk of Vascular Dementia: A Mendelian Randomization Study.Nutrients. 2022 Dec 23;15(1):69. doi: 10.3390/nu15010069. Nutrients. 2022. PMID: 36615727 Free PMC article.
-
Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels.Int J Mol Sci. 2022 Aug 20;23(16):9417. doi: 10.3390/ijms23169417. Int J Mol Sci. 2022. PMID: 36012684 Free PMC article. Review.
-
Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis.JAMA Cardiol. 2018 Jan 1;3(1):26-33. doi: 10.1001/jamacardio.2017.4293. JAMA Cardiol. 2018. PMID: 29188294 Free PMC article. Review.
Cited by
-
Causal relationship between nutritional assessment phenotypes and heart failure: A Mendelian randomization study.Heliyon. 2024 Mar 26;10(7):e28619. doi: 10.1016/j.heliyon.2024.e28619. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38590862 Free PMC article.
-
Cholesteryl Ester Transfer Protein (CETP) Variations in Relation to Lipid Profiles and Cardiovascular Diseases: An Update.Curr Pharm Des. 2024;30(10):742-756. doi: 10.2174/0113816128284695240219093612. Curr Pharm Des. 2024. PMID: 38425105 Review.
-
Proteomic Associations of Adverse Outcomes in Human Heart Failure.J Am Heart Assoc. 2024 Mar 5;13(5):e031154. doi: 10.1161/JAHA.123.031154. Epub 2024 Feb 29. J Am Heart Assoc. 2024. PMID: 38420755 Free PMC article.
-
Proteome-wide mendelian randomization investigates potential associations in heart failure and its etiology: emphasis on PCSK9.BMC Med Genomics. 2024 Feb 21;17(1):59. doi: 10.1186/s12920-024-01826-6. BMC Med Genomics. 2024. PMID: 38383373 Free PMC article.
-
The landscape of the methodology in drug repurposing using human genomic data: a systematic review.Brief Bioinform. 2024 Jan 22;25(2):bbad527. doi: 10.1093/bib/bbad527. Brief Bioinform. 2024. PMID: 38279645
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous